ENTERA BIO LTD (ENTX) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ENTX • IL0011429839

1.04 USD
-0.13 (-11.11%)
At close: Feb 6, 2026
1.07 USD
+0.03 (+2.88%)
Pre-Market: 2/9/2026, 8:02:24 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

ENTX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. ENTX has a great financial health rating, but its profitability evaluates not so good. ENTX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ENTX has reported negative net income.
  • In the past year ENTX has reported a negative cash flow from operations.
  • In the past 5 years ENTX always reported negative net income.
  • In the past 5 years ENTX always reported negative operating cash flow.
ENTX Yearly Net Income VS EBIT VS OCF VS FCFENTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • ENTX has a Return On Assets of -61.93%. This is comparable to the rest of the industry: ENTX outperforms 41.68% of its industry peers.
  • The Return On Equity of ENTX (-70.77%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -61.93%
ROE -70.77%
ROIC N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ENTX Yearly ROA, ROE, ROICENTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ENTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ENTX Yearly Profit, Operating, Gross MarginsENTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • ENTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for ENTX has been increased compared to 1 year ago.
  • Compared to 5 years ago, ENTX has more shares outstanding
  • There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ENTX Yearly Shares OutstandingENTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
ENTX Yearly Total Debt VS Total AssetsENTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

  • ENTX has an Altman-Z score of 2.35. This is not the best score and indicates that ENTX is in the grey zone with still only limited risk for bankruptcy at the moment.
  • ENTX has a better Altman-Z score (2.35) than 67.50% of its industry peers.
  • There is no outstanding debt for ENTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.35
ROIC/WACCN/A
WACC8.73%
ENTX Yearly LT Debt VS Equity VS FCFENTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M

2.3 Liquidity

  • A Current Ratio of 10.83 indicates that ENTX has no problem at all paying its short term obligations.
  • ENTX has a better Current ratio (10.83) than 85.09% of its industry peers.
  • ENTX has a Quick Ratio of 10.83. This indicates that ENTX is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Quick ratio value of 10.83, ENTX belongs to the best of the industry, outperforming 85.09% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.83
Quick Ratio 10.83
ENTX Yearly Current Assets VS Current LiabilitesENTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 50.00% over the past year.
  • Measured over the past years, ENTX shows a decrease in Revenue. The Revenue has been decreasing by -5.49% on average per year.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%-100%

3.2 Future

  • ENTX is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -66.57% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.24%
EPS Next 2Y-66.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ENTX Yearly Revenue VS EstimatesENTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2025 0 200K 400K
ENTX Yearly EPS VS EstimatesENTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ENTX. In the last year negative earnings were reported.
  • Also next year ENTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ENTX Price Earnings VS Forward Price EarningsENTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ENTX Per share dataENTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • ENTX's earnings are expected to decrease with -66.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-66.57%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ENTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ENTERA BIO LTD

NASDAQ:ENTX (2/6/2026, 8:00:01 PM)

Premarket: 1.07 +0.03 (+2.88%)

1.04

-0.13 (-11.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14
Earnings (Next)03-26
Inst Owners19.74%
Inst Owner Change-1.14%
Ins Owners2.41%
Ins Owner Change2.1%
Market Cap47.69M
Revenue(TTM)124.00K
Net Income(TTM)-10.78M
Analysts82.86
Price Target10.2 (880.77%)
Short Float %0.29%
Short Ratio0.57
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)35.14%
Min EPS beat(2)23.75%
Max EPS beat(2)46.52%
EPS beat(4)4
Avg EPS beat(4)70.19%
Min EPS beat(4)23.75%
Max EPS beat(4)184.03%
EPS beat(8)7
Avg EPS beat(8)32.3%
EPS beat(12)10
Avg EPS beat(12)25.72%
EPS beat(16)14
Avg EPS beat(16)25.06%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)18.18%
EPS NY rev (1m)12.5%
EPS NY rev (3m)12.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 384.63
P/FCF N/A
P/OCF N/A
P/B 3.13
P/tB 3.13
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0
BVpS0.33
TBVpS0.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -61.93%
ROE -70.77%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-92.24%
ROA(5y)-87.81%
ROE(3y)-104.97%
ROE(5y)-103.66%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 244.12%
Cap/Sales 66.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.83
Quick Ratio 10.83
Altman-Z 2.35
F-Score5
WACC8.73%
ROIC/WACCN/A
Cap/Depr(3y)40.07%
Cap/Depr(5y)48.71%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y-14.24%
EPS Next 2Y-66.57%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y-31.78%
Revenue growth 5Y-5.49%
Sales Q2Q%-100%
Revenue Next Year-69.78%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-7.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.46%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.54%
OCF growth 3YN/A
OCF growth 5YN/A

ENTERA BIO LTD / ENTX FAQ

What is the fundamental rating for ENTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to ENTX.


Can you provide the valuation status for ENTERA BIO LTD?

ChartMill assigns a valuation rating of 0 / 10 to ENTERA BIO LTD (ENTX). This can be considered as Overvalued.


How profitable is ENTERA BIO LTD (ENTX) stock?

ENTERA BIO LTD (ENTX) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ENTERA BIO LTD?

The Earnings per Share (EPS) of ENTERA BIO LTD (ENTX) is expected to decline by -14.24% in the next year.